ArticleOncotarget2017
Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Identification of biomarkers associated with diagnosis of gastroesophageal junction adenocarcinoma and their correlation with immune infiltration.Discover oncology · 2026Article
- BUB1 in cancer genetics and oncogenomics: from chromosomal instability to therapeutic vulnerabilities.Frontiers in genetics · 2026Review
- BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.BMC immunology · 2025Article
- Expression and clinical significance of BUB1 in esophageal cancer.American journal of translational research · 2025Article
- BUB1 induces AKT/mTOR pathway activity to promote EMT induction in human small cell lung cancer.Scientific reports · 2024Article
- Key candidate genes and pathways in T lymphoblastic leukemia/lymphoma identified by bioinformatics and serological analyses.Frontiers in immunology · 2024Article
- Identification of functional genes regulating gastric cancer progression using integrated bioinformatics analysis.World journal of clinical cases · 2023Article
- Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis.Aging · 2023Article
- KIF4A knockdown suppresses ovarian cancer cell proliferation and induces apoptosis by downregulating BUB1 expression.Molecular medicine reports · 2021Article
- Article
- Increased Expression ofJournal of personalized medicine · 2021Article
- Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma.Cancers · 2020Article
- Bioinformatics analysis of BUB1 expression and gene regulation network in lung adenocarcinoma.Translational cancer research · 2020Article
- The Expression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological Indicators: A Retrospective Study.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- [BUB1 gene is highly expressed in gastric cancer:analysis based on Oncomine database and bioinformatics].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation.Oncology letters · 2020Article
- Identification of differentially expressed protein-coding genes in lung adenocarcinomas.Experimental and therapeutic medicine · 2020Article
- Prognostic Prediction Using a Stemness Index-Related Signature in a Cohort of Gastric Cancer.Frontiers in molecular biosciences · 2020Article
- Screening of differential expressed genes from gene chip and sequencing data and evaluate its prognostic values in males with digestive system neoplasms.Translational cancer research · 2019Article
- Identification of key genes and microRNAs involved in kidney Wilms tumor by integrated bioinformatics analysis.Experimental and therapeutic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Gastric adenocarcinomas are associated with a poor prognosis due to the fact that the tumor has often metastasized by the time of diagnosis and prognostic markers are urgently needed to tailor treatment. We examined the expression of the mitotic spindle checkpoint protein BUB1 (budding uninhibited by benzimidazoles 1) and Ki-67 protein expression by immunohistochemistry in 218 patients with primary gastric adenocarcinomas. Tumors with low frequency of BUB1 expression were associated with larger tumor size (pT) (p < 0.001), higher incidence of lymph node metastases (pN) (p = 0.027), distant metastases (pM) (p = 0.006) and higher UICC stage (p < 0.001). Furthermore, BUB1 expression was inversely correlated with residual tumor stage (p = 0.038). Abundant BUB1 protein expression correlated with frequent Ki-67 protein expression (p < 0.001) and low BUB1 expression was associated with shorter survival (p < 0.001). Univariate and multivariate analyses confirmed BUB1 to be an independent prognostic marker in gastric cancer (p = 0.021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.